Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
09/20/2024 | Press release | Distributed by Public on 09/20/2024 12:42
Please select the service you want to use:
Smartlinks | PannErgy Nyrt. | Company News | Buyback, Treasury Shares and Liquidity Agreements | Securities Issuers | Specialty Chemical Companies | London Stock Exchange (LSE) | Frankfurt Stock Exchange | Berlin Stock Exchange | Dusseldorf Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | Budapest Stock Exchange | BX Swiss | Cboe BXE Europe | Cboe CXE Europe | Cboe Off Exchange | SIGMA X MTF | Turquoise
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact